Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer
Interventions: DRUG: paclitaxel albumin-stabilized nanoparticle formulation|BIOLOGICAL: bevacizumab|DRUG: erlotinib hydrochloride
Sponsor: University of Washington
Collaborators: National Cancer Institute (NCI)